Stock listing

NASDAQ:IRWD Ironwood Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Ironwood Pharmaceuticals, Inc.

Follow Ironwood Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IRWD

$3.56 USD +0.06 (+1.7%)

Close on Oct 19, 2026

Since Jul 6, 2026 -18.7% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$3.48 – $3.59 USDOct 19, 2026
Volume
1.68M sharesOct 19, 2026
Market value
$588.3M USDAt the close on Oct 19, 2026 · price × 165.2M shares outstanding
Ironwood Pharmaceuticals, Inc. logo
Ticker
NASDAQ:IRWD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Ironwood Pharmaceuticals (NASDAQ:IRWD) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:30 AM ET

    Watch Transcript

  • Ironwood Pharmaceuticals (NASDAQ:IRWD) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:30 AM ET

    Watch Transcript

  • Ironwood Pharmaceuticals (NASDAQ:IRWD) Q4 2025 Earnings Call

    Wed, Feb 25, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

Oct 16, 2026

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Sep 3, 2026

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Aug 6, 2026

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

Jul 30, 2026

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

Jul 14, 2026

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

May 27, 2026

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance

May 8, 2026

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

May 4, 2026

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Apr 30, 2026

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Apr 23, 2026

All Ironwood Pharmaceuticals, Inc. news

Decks

Ironwood Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 139 in all · newest Oct 16, 2026 · oldest 2019
Calls
18 calls with a replay · 18 with a transcript · latest Aug 6, 2026
Decks
49 decks · latest Aug 6, 2026

Where Ironwood Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IRWD · Home listing · This pageNASDAQUnited StatesUSD
gettex:I76gettexGermanyEUR
BOATS:IRWDBOATSUnited StatesUSD
LS Exchange:A0X789LS ExchangeGermanyEUR
Lang & Schwarz:A0X789Lang & SchwarzGermanyEUR
Tradegate:I76TradegateGermanyEUR
BX Swiss:I76BX SwissSwitzerlandCHF
Dusseldorf:I76DusseldorfGermanyEUR
Frankfurt:I76FrankfurtGermanyEUR
Munich:I76MunichGermanyEUR
Stuttgart:I76StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Ironwood Pharmaceuticals, Inc.